948 Final results from AIPAC: A phase IIb comparing eftilagimod alpha (a soluble LAG-3 protein) vs. placebo in combination with weekly paclitaxel in HR+ HER2- MBC

Christian Mueller, Frederik Marmé, Luc Dirix, Frederic Triebel, Hans Wildiers, Peter Vuylsteke, Chrystelle Brignone, Jens Huober, Sherko Kümmel, Anne Armstrong, Eveline De Cuypere, Florence Dalenc, Steven Chan, Carolina Pia Schröder, Jean-Philippe Jacquin, Etienne Brain, Zsuzsanna Pápai

Open source

DOI: 10.1136/jitc-2021-sitc2021.948
Published: November
Container: Journal for ImmunoTherapy of Cancer
Publisher: Not recorded
Open access: yes

Credibility signals

uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
supportingDirectory of Open Access Journals: A matching record was returned by DOAJ. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1136/jitc-2021-sitc2021.948,
  title = {948 Final results from AIPAC: A phase IIb comparing eftilagimod alpha (a soluble LAG-3 protein) vs. placebo in combination with weekly paclitaxel in HR+ HER2- MBC},
  author = {Christian Mueller and Frederik Marmé and Luc Dirix and Frederic Triebel and Hans Wildiers and Peter Vuylsteke and Chrystelle Brignone and Jens Huober and Sherko Kümmel and Anne Armstrong and Eveline De Cuypere and Florence Dalenc and Steven Chan and Carolina Pia Schröder and Jean-Philippe Jacquin and Etienne Brain and Zsuzsanna Pápai},
  year = {2021},
  journal = {Journal for ImmunoTherapy of Cancer},
  doi = {10.1136/jitc-2021-sitc2021.948},
  url = {https://doi.org/10.1136/jitc-2021-sitc2021.948}
}

RIS

TY  - JOUR
TI  - 948 Final results from AIPAC: A phase IIb comparing eftilagimod alpha (a soluble LAG-3 protein) vs. placebo in combination with weekly paclitaxel in HR+ HER2- MBC
AU  - Christian Mueller
AU  - Frederik Marmé
AU  - Luc Dirix
AU  - Frederic Triebel
AU  - Hans Wildiers
AU  - Peter Vuylsteke
AU  - Chrystelle Brignone
AU  - Jens Huober
AU  - Sherko Kümmel
AU  - Anne Armstrong
AU  - Eveline De Cuypere
AU  - Florence Dalenc
AU  - Steven Chan
AU  - Carolina Pia Schröder
AU  - Jean-Philippe Jacquin
AU  - Etienne Brain
AU  - Zsuzsanna Pápai
PY  - 2021
JO  - Journal for ImmunoTherapy of Cancer
DO  - 10.1136/jitc-2021-sitc2021.948
UR  - https://doi.org/10.1136/jitc-2021-sitc2021.948
ER  -

APA

Mueller, C., Marmé, F., Dirix, L., Triebel, F., Wildiers, H., Vuylsteke, P., Brignone, C., Huober, J., Kümmel, S., Armstrong, A., Cuypere, E. D., Dalenc, F., Chan, S., Schröder, C. P., Jacquin, J., Brain, E., & Pápai, Z. (2021). 948 Final results from AIPAC: A phase IIb comparing eftilagimod alpha (a soluble LAG-3 protein) vs. placebo in combination with weekly paclitaxel in HR+ HER2- MBC. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2021-sitc2021.948

Source records

doaj · retrieved 2026-09-26T00:56:44.407Z